KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Non-Current Assets (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 9 years of Non-Current Assets data on record, last reported at -$1.9 billion in Q4 2025.

  • For Q4 2025, Non-Current Assets fell 199.87% year-over-year to -$1.9 billion; the TTM value through Dec 2025 reached -$3.3 billion, down 173.12%, while the annual FY2025 figure was -$1.9 billion, 199.87% down from the prior year.
  • Non-Current Assets reached -$1.9 billion in Q4 2025 per AMRX's latest filing, down from -$1.8 billion in the prior quarter.
  • Across five years, Non-Current Assets topped out at $2.4 billion in Q4 2021 and bottomed at -$1.9 billion in Q4 2025.
  • Average Non-Current Assets over 5 years is $321.7 million, with a median of $303.2 million recorded in 2023.
  • Peak YoY movement for Non-Current Assets: rose 0.63% in 2022, then crashed 199.87% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $2.4 billion in 2021, then fell by 1.32% to $2.4 billion in 2022, then fell by 12.26% to $2.1 billion in 2023, then decreased by 8.64% to $1.9 billion in 2024, then tumbled by 199.87% to -$1.9 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were -$1.9 billion in Q4 2025, -$1.8 billion in Q3 2025, and -$1.5 billion in Q1 2025.